Skip to main content
. 2022 Sep 2;18(9):e1010362. doi: 10.1371/journal.pgen.1010362

Fig 4. PTPRH mutant cell lines respond to TKI osimertinib.

Fig 4

Pooled PTPRH KO cells have increased proliferation, and PTPRH mutant cell lines respond to osimertinib. A) Western blotting confirms increased p-EGFR at tyrosine 1197 within pooled KO cells compared to WT cells. B) Cellular growth curves show increased growth in PTPRH pooled KO cells as compared to WT cells. C) MTT assays completed with H23 WT and H23 PTPRH pooled KO cells show increased proliferation. D) Two PTPRH mutant cell lines (WT for EGFR) from human non-small cell lung cancer tumors show response to the TKI osimertinib in vitro. E) Treatment plan for in vivo treatment of H2228 PTPRH mutant cell line. Either H1975 (L858R EGFR mutant) or H2228 (Q887P PTPRH mutant) cells were injected into the left flank of nude mice. Mice were then randomized into two treatment groups, vehicle control or osimertinib. H1975 mice were treated with 25 mg/kg of osimertinib and H2228 injected mice were treated with either 25 mg/kg or 50 mg/kg of osimertinib. F) in vivo drug curve showing response to osimertinib of H1975 EGFR mutant injected mice. G) in vivo drug curve showing response to osimertinib of H2228 PTPRH mutant injected mice.